cytosine has been researched along with abacavir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Marzocchetti, A; Pompucci, A; Scoppettuolo, G; Tumbarello, M; Vago, G | 1 |
| Calvez, V; Dabis, F; Danaviah, S; de Oliveira, T; Derache, A; Giandhari, J; Gupta, RK; Iwuji, CC; Marcelin, AG; Pillay, D | 1 |
1 trial(s) available for cytosine and abacavir
| Article | Year |
|---|---|
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cytosine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; South Africa; Tenofovir; Viral Load; Young Adult | 2019 |
1 other study(ies) available for cytosine and abacavir
| Article | Year |
|---|---|
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity?
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Brain; CD4 Lymphocyte Count; Cidofovir; Cytosine; Dideoxynucleosides; Encephalitis; False Negative Reactions; Fatal Outcome; Humans; Immunocompromised Host; Indinavir; JC Virus; Lamivudine; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Organophosphonates; Substance Abuse, Intravenous; Time Factors; Virus Activation; Zidovudine | 2004 |